{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:45:21Z","timestamp":1790919921284,"version":"4.1.0"},"reference-count":94,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:00:00Z","timestamp":1239753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Acute lymphoblastic leukaemia (ALL) is a heterogeneous disease that is often associated with several chromosomal and molecular abnormalities. Patients who have the Philadelphia (Ph) chromosome and associated <jats:italic>BCR\u2010ABL1<\/jats:italic> oncogene have a particularly poor prognosis. Currently, allogeneic haematopoietic stem cell transplantation (allo\u2010HSCT) is the only known curative treatment for Ph+ ALL and facilitating allo\u2010HSCT in eligible patients is a key treatment goal. However, many patients relapse after allo\u2010HSCT, particularly those with measurable residual disease prior to transplantation, and a significant percentage of patients are ineligible for allo\u2010HSCT, particularly older patients. Hence, many patients require additional\/alternative therapies to prolong survival. Studies are ongoing to determine the most effective first\u2010line drug regimens for patients who subsequently undergo allo\u2010HSCT and ineligible patients. Tyrosine kinase inhibitors targeted to Bcr\u2010Abl are important novel therapies for Ph+ ALL. Although imatinib administered in combination with chemotherapy is established as the current first\u2010line strategy, relapse is common, even among allo\u2010HSCT recipients. Emerging data indicate that more potent multi\u2010targeted kinase inhibitors (including dasatinib, nilotinib, and bosutinib) have promising efficacy in the first\u2010 or second\u2010line setting. Here, the evidence base for existing drug treatments for Ph+ ALL is discussed and emerging therapeutic strategies are explored.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2009.07666.x","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T09:41:48Z","timestamp":1239788508000},"page":"581-597","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome\u2010positive acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"145","author":[{"given":"Franz","family":"Gruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701258370"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421402"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703899"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065655"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004580"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019836"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.6.1572"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080838"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.045260"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M402290200"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403307"},{"key":"e_1_2_10_13_1","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant\u2010related mortality","volume":"91","author":"Deininger M.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404320"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0704"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.2.690"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705904"},{"key":"e_1_2_10_19_1","first-page":"8","article-title":"Does imatinib change the outcome in Philapdelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII\/ECOG2993 study","volume":"110","author":"Fielding A.K.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"e_1_2_10_20_1","article-title":"Dasatinib monotherapy as 1st line treatment of Ph acute lymphoblastic leukemia (ALL) patients: update of the GIMEMA LAL1205 study","volume":"93","author":"Foa R.","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11525"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.20.1641"},{"issue":"1","key":"e_1_2_10_23_1","first-page":"160","article-title":"Bosutinib (SKI\u2010606) shows high tolerability and clinical activity in patients with Philadelphia chromosome positive leukemias","volume":"93","author":"Gambacorti\u2010Passerini C.","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-025049"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1536"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001625755"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1343"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606509103"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-112631"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983538"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403257"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23666"},{"key":"e_1_2_10_37_1","first-page":"659","article-title":"Comparison of allele specific oligonucleotide\u2010polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib","volume":"91","author":"Kang H.Y.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_10_40_1","article-title":"A phase I study of INNO\u2010406 in patients with advanced Philadelphia (Ph+) chromosome\u2010positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors","volume":"110","author":"Kantarjian H.M.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-096396"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-10-200305200-00010"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011908"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143115"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3785"},{"key":"e_1_2_10_46_1","article-title":"Predictive potential of minimal residual disease level after the first imatinib cycle on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome\u2010positive acute lymphoblastic leukemia","volume":"110","author":"Lee S.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3058"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.5.1366.1366"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11960"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06866"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.46"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1731"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0181"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22631"},{"key":"e_1_2_10_59_1","first-page":"2815","article-title":"Nilotinib in patients with relapsed\/refractory Philadelphia chromosome\u2010positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib","volume":"110","author":"Ottmann O.G.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03523.x"},{"key":"e_1_2_10_61_1","first-page":"4674","article-title":"Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome\u2010positive acute leukemias treated with imatinib mesylate","volume":"9","author":"Pfeifer H.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-052373"},{"key":"e_1_2_10_63_1","article-title":"More rapid outgrowth kinetics of BCR\u2010ABL mutations in advanced versus newly diagnosed Philadelphia\u2010positive acute lymphoblastic leukemia: clinical\u2010translational evidence for a contributory role of non\u2010mutational resistance mechanisms","volume":"110","author":"Pfeifer H.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"e_1_2_10_64_1","article-title":"Dasatinib efficacy in patients with imatinib\u2010resistant\/\u2010intolerant Philadelphia\u2010chromosome\u2010positive acute lymphoblastic leukemia: 24\u2010month data from START\u2010L","volume":"93","author":"Porkka K.","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400567"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023001"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2602"},{"key":"e_1_2_10_69_1","article-title":"Phase II study of combination of the hyperCVAD regimen with dasatinib in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"26","author":"Ravandi F.","year":"2008","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"e_1_2_10_70_1","first-page":"4","article-title":"Improved early event free survival (EFS) in children with Philadelphia chromosome\u2010positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children\u2019s Oncology Group (COG) study AALL0031","volume":"110","author":"Schultz K.R.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_10_71_1","first-page":"196","article-title":"Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance","volume":"5","author":"Secker\u2010Walker L.M.","year":"1991","journal-title":"Leukemia"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30890"},{"key":"e_1_2_10_74_1","first-page":"47","article-title":"Interim results from a phase I clinical trial of the BCR\u2010ABL inhibitor XL228 in drug\u2010resistant Ph+ leukemias","volume":"93","author":"Shah P.","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2004.031112"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10822"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)70011-1"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03881.x"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2958"},{"key":"e_1_2_10_81_1","first-page":"7019","article-title":"Outcome after frontline therapy with the hyper\u2010CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL)","volume":"26","author":"Thomas D.A.","year":"2008","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting Proceedings)"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052746"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1746"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4386"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1036"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn188"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109330"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705148"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2177"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11891"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-013250"},{"key":"e_1_2_10_95_1","first-page":"367","article-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: Preliminary results of the CA180018 Phase I\/II study from the ITCC consortium","author":"Zwaan C.M.","year":"2008","journal-title":"Haematologica"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2009.07666.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2009.07666.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:43:33Z","timestamp":1695919413000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2009.07666.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,11]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1365-2141.2009.07666.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07666.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,11]]},"assertion":[{"value":"2009-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}